S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.38 (-1.77%)
AAPL   146.79 (-0.69%)
MSFT   250.01 (-1.96%)
META   122.68 (-0.66%)
GOOGL   99.49 (-0.95%)
AMZN   90.96 (-3.37%)
TSLA   182.43 (-6.38%)
NVDA   165.98 (-1.65%)
NIO   12.81 (-2.44%)
BABA   90.30 (+0.27%)
AMD   73.56 (-1.89%)
T   18.71 (-1.63%)
MU   54.05 (-1.15%)
CGC   4.33 (+0.93%)
F   13.41 (-3.25%)
GE   84.66 (-2.56%)
DIS   95.78 (-3.67%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.75 (-0.31%)
NFLX   312.65 (-2.42%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.38 (-1.77%)
AAPL   146.79 (-0.69%)
MSFT   250.01 (-1.96%)
META   122.68 (-0.66%)
GOOGL   99.49 (-0.95%)
AMZN   90.96 (-3.37%)
TSLA   182.43 (-6.38%)
NVDA   165.98 (-1.65%)
NIO   12.81 (-2.44%)
BABA   90.30 (+0.27%)
AMD   73.56 (-1.89%)
T   18.71 (-1.63%)
MU   54.05 (-1.15%)
CGC   4.33 (+0.93%)
F   13.41 (-3.25%)
GE   84.66 (-2.56%)
DIS   95.78 (-3.67%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.75 (-0.31%)
NFLX   312.65 (-2.42%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.38 (-1.77%)
AAPL   146.79 (-0.69%)
MSFT   250.01 (-1.96%)
META   122.68 (-0.66%)
GOOGL   99.49 (-0.95%)
AMZN   90.96 (-3.37%)
TSLA   182.43 (-6.38%)
NVDA   165.98 (-1.65%)
NIO   12.81 (-2.44%)
BABA   90.30 (+0.27%)
AMD   73.56 (-1.89%)
T   18.71 (-1.63%)
MU   54.05 (-1.15%)
CGC   4.33 (+0.93%)
F   13.41 (-3.25%)
GE   84.66 (-2.56%)
DIS   95.78 (-3.67%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.75 (-0.31%)
NFLX   312.65 (-2.42%)
S&P 500   3,998.84 (-1.79%)
DOW   33,947.10 (-1.40%)
QQQ   287.38 (-1.77%)
AAPL   146.79 (-0.69%)
MSFT   250.01 (-1.96%)
META   122.68 (-0.66%)
GOOGL   99.49 (-0.95%)
AMZN   90.96 (-3.37%)
TSLA   182.43 (-6.38%)
NVDA   165.98 (-1.65%)
NIO   12.81 (-2.44%)
BABA   90.30 (+0.27%)
AMD   73.56 (-1.89%)
T   18.71 (-1.63%)
MU   54.05 (-1.15%)
CGC   4.33 (+0.93%)
F   13.41 (-3.25%)
GE   84.66 (-2.56%)
DIS   95.78 (-3.67%)
AMC   7.47 (-8.57%)
PYPL   73.62 (-1.39%)
PFE   50.75 (-0.31%)
NFLX   312.65 (-2.42%)
NASDAQ:CYAD

Celyad Oncology - CYAD Stock Forecast, Price & News

$1.01
+0.02 (+2.05%)
(As of 12/2/2022 03:01 PM ET)
Add
Compare
Today's Range
$1.00
▼
$1.01
50-Day Range
$0.95
▼
$1.45
52-Week Range
$0.95
▼
$5.32
Volume
200 shs
Average Volume
47,509 shs
Market Capitalization
$22.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.89

Celyad Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
582.2% Upside
$6.89 Price Target
Short Interest
Bearish
0.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.45) to ($1.61) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

933rd out of 1,033 stocks

Pharmaceutical Preparations Industry

457th out of 502 stocks

See Top Rated MarketRank™ Stocks Here
CYAD stock logo

About Celyad Oncology (NASDAQ:CYAD) Stock

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

CYAD Stock News Headlines

November 11, 2022 | reuters.com
Celyad Oncology SA
November 10, 2022 | finance.yahoo.com
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
October 12, 2022 | finance.yahoo.com
Celyad Oncology Provides Strategic Update
September 20, 2022 | finance.yahoo.com
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
August 5, 2022 | seekingalpha.com
Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript
August 1, 2022 | nasdaq.com
Celyad: FDA Lifts Clinical Hold On CYAD-101-002 Phase 1b Trial
August 1, 2022 | markets.businessinsider.com
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 1, 2022 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
August 1, 2022 | finance.yahoo.com
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
July 28, 2022 | finance.yahoo.com
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
July 19, 2022 | seekingalpha.com
Celyad: Probably Still Top-Notch In Oncology
June 24, 2022 | finance.yahoo.com
Celyad Oncology Announces Leadership Updates
May 25, 2022 | finance.yahoo.com
Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know
May 17, 2022 | finance.yahoo.com
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
May 5, 2022 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 5, 2022 | seekingalpha.com
Celyad Oncology reports Q1 results
May 5, 2022 | finance.yahoo.com
CORRECTING AND REPLACING: Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 5, 2022 | finance.yahoo.com
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
March 26, 2022 | seekingalpha.com
Celyad Oncology GAAP EPS of -€1.70
March 24, 2022 | finance.yahoo.com
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
March 18, 2022 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
March 17, 2022 | finance.yahoo.com
Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
March 2, 2022 | seekingalpha.com
Celyad phase 1b colorectal cancer trial put on hold by FDA citing safety after 2 deaths
March 2, 2022 | finanznachrichten.de
Celyad Oncology SA: Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
March 2, 2022 | finance.yahoo.com
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
See More Headlines
Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

CYAD Company Calendar

Today
12/05/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYAD
CUSIP
N/A
CIK
1637890
Web
www.celyad.com
Phone
(210) 039-4100
Fax
321-039-4141
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.89
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$2.78
Forecasted Upside/Downside
+582.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
1.71
Quick Ratio
2.58

Sales & Book Value

Annual Sales
$10,000.00
Price / Sales
2,281.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.29 per share
Price / Book
0.44

Miscellaneous

Outstanding Shares
22,594,000
Free Float
22,382,000
Market Cap
$22.82 million
Optionable
Not Optionable
Beta
1.23

Key Executives

  • Mr. Michel E. J. Lussier BME (Age 66)
    M.B.A., M.S., MBA, MS BME, Co-Founder, CFO, Interim CEO & Director
    Comp: $82.55k
  • Mr. David Georges
    VP of Fin. & Admin.
  • Sara Zelkovic
    Communications & Investor Relations Director
  • Mr. Philippe Dechamps (Age 52)
    Chief Legal Officer & Corp. Sec.
  • Mr. Philippe Nobels (Age 56)
    Chief HR Officer & VP of HR
  • Dr. Charles Q. Morris M.D. (Age 57)
    MBChB, MRCP (UK), Ph.D., Chief Medical Officer
  • Ms. An Phan
    Head of Legal
  • Mr. Hannes Iserentant
    Head of Intellectual Property
  • Dr. Frédéric Lehmann (Age 58)
    VP of Clinical Devel. & Medical Affairs

Key Competitors

View All Competitors













CYAD Stock - Frequently Asked Questions

Should I buy or sell Celyad Oncology stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celyad Oncology in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CYAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CYAD, but not buy additional shares or sell existing shares.
View CYAD analyst ratings or view top-rated stocks.

What is Celyad Oncology's stock price forecast for 2023?

4 analysts have issued 12-month price objectives for Celyad Oncology's shares. Their CYAD share price forecasts range from $2.78 to $11.00. On average, they anticipate the company's share price to reach $6.89 in the next year. This suggests a possible upside of 582.2% from the stock's current price.
View analysts price targets for CYAD or view top-rated stocks among Wall Street analysts.

How have CYAD shares performed in 2022?

Celyad Oncology's stock was trading at $3.66 at the start of the year. Since then, CYAD stock has decreased by 72.4% and is now trading at $1.01.
View the best growth stocks for 2022 here.

What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).

When did Celyad Oncology IPO?

(CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

What is Celyad Oncology's stock symbol?

Celyad Oncology trades on the NASDAQ under the ticker symbol "CYAD."

How do I buy shares of Celyad Oncology?

Shares of CYAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celyad Oncology's stock price today?

One share of CYAD stock can currently be purchased for approximately $1.01.

How much money does Celyad Oncology make?

Celyad Oncology (NASDAQ:CYAD) has a market capitalization of $22.82 million and generates $10,000.00 in revenue each year.

How can I contact Celyad Oncology?

Celyad Oncology's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The official website for the company is www.celyad.com. The company can be reached via phone at (210) 039-4100 or via fax at 321-039-4141.

This page (NASDAQ:CYAD) was last updated on 12/5/2022 by MarketBeat.com Staff